(Q37641329)

English

Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus

scientific article published on December 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Scott R Drab

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

12 Pt 2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

43S-54S

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Actions of insulin beyond glycemic control: a perspective on insulin detemir

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Small-molecule agonists for the glucagon-like peptide 1 receptor

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Unraveling the science of incretin biology

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Comment on: Lachin et al. (2007) The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the diabetes control and complications trial: Diabetes 56:1913-1921, 2007.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

MT1-MMP expression in first-trimester placental tissue is upregulated in type 1 diabetes as a result of elevated insulin and tumor necrosis factor-alpha levels

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Incretin hormone mimetics and analogues in diabetes therapeutics

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.43S

21 January 2018

Identifiers

10.1592/PHCO.29.PT2.43S

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37641329&oldid=2222946763"